Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22529429 | 0.92 | TP53 (0.39) | NOTUMTP53CREBBPMAOAACHE | |
| SCHEMBL14688848 | 0.92 | TP53 (0.42) | NOTUMTP53CREBBPMAOAACHE | |
| SCHEMBL2360361 | 0.81 | CCNB2 (0.36) | NOTUMTP53CREBBPMAOAACHE | |
| SCHEMBL2360526 | 0.79 | TP53 (0.43) | NOTUMTP53CREBBPKDM4EALDH1A1 | |
| SCHEMBL2360304 | 0.77 | TP53 (0.40) | TP53CREBBPMAOAACHEKDM4E | |
| SCHEMBL2360890 | 0.74 | TP53 (0.39) | NOTUMTP53CREBBPKDM4EALDH1A1 | |
| SCHEMBL22529425 | 0.74 | TP53 (0.37) | NOTUMTP53CREBBPKDM4EALDH1A1 | |
| SCHEMBL2365506 | 0.69 | TP53 (0.47) | TP53CREBBPKDM4EALDH1A1HPGD | |
| SCHEMBL22529386 | 0.69 | TP53 (0.44) | TP53CREBBPMAOAACHEKDM4E | |
| SCHEMBL14688409 | 0.68 | ALDH1A1 (0.40) | TP53ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| EP-2531029-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | Radius Health, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097496-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | NOTUM 2194/4885TP53 4026/4885CREBBP 318/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | NOTUM 2194/4885TP53 4026/4885CREBBP 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.